Cargando…

Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells

BACKGROUND: Bisdioxopiperazine anti-cancer agents are inhibitors of eukaryotic DNA topoisomerase II, sequestering this protein as a non-covalent protein clamp on DNA. It has been suggested that such complexes on DNA represents a novel form of DNA damage to cells. In this report, we characterise the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Lars H, Dejligbjerg, Marielle, Hansen, Lasse T, Grauslund, Morten, Jensen, Peter B, Sehested, Maxwell
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545072/
https://www.ncbi.nlm.nih.gov/pubmed/15575955
http://dx.doi.org/10.1186/1471-2210-4-31
_version_ 1782122193448075264
author Jensen, Lars H
Dejligbjerg, Marielle
Hansen, Lasse T
Grauslund, Morten
Jensen, Peter B
Sehested, Maxwell
author_facet Jensen, Lars H
Dejligbjerg, Marielle
Hansen, Lasse T
Grauslund, Morten
Jensen, Peter B
Sehested, Maxwell
author_sort Jensen, Lars H
collection PubMed
description BACKGROUND: Bisdioxopiperazine anti-cancer agents are inhibitors of eukaryotic DNA topoisomerase II, sequestering this protein as a non-covalent protein clamp on DNA. It has been suggested that such complexes on DNA represents a novel form of DNA damage to cells. In this report, we characterise the cytotoxicity and DNA damage induced by the bisdioxopiperazine ICRF-187 by a combination of genetic and molecular approaches. In addition, the well-established topoisomerase II poison m-AMSA is used for comparison. RESULTS: By utilizing a panel of Saccharomyces cerevisiae single-gene deletion strains, homologous recombination was identified as the most important DNA repair pathway determining the sensitivity towards ICRF-187. However, sensitivity towards m-AMSA depended much more on this pathway. In contrast, disrupting the post replication repair pathway only affected sensitivity towards m-AMSA. Homologous recombination (HR) defective irs1SF chinese hamster ovary (CHO) cells showed increased sensitivity towards ICRF-187, while their sensitivity towards m-AMSA was increased even more. Furthermore, complementation of the XRCC3 deficiency in irs1SF cells fully abrogated hypersensitivity towards both drugs. DNA-PK(cs )deficient V3-3 CHO cells having reduced levels of non-homologous end joining (NHEJ) showed slightly increased sensitivity to both drugs. While exposure of human small cell lung cancer (SCLC) OC-NYH cells to m-AMSA strongly induced γH2AX, exposure to ICRF-187 resulted in much less induction, showing that ICRF-187 generates fewer DNA double strand breaks than m-AMSA. Accordingly, when yeast cells were exposed to equitoxic concentrations of ICRF-187 and m-AMSA, the expression of DNA damage-inducible genes showed higher levels of induction after exposure to m-AMSA as compared to ICRF-187. Most importantly, ICRF-187 stimulated homologous recombination in SPD8 hamster lung fibroblast cells to lower levels than m-AMSA at all cytotoxicity levels tested, showing that the mechanism of action of bisdioxopiperazines differs from that of classical topoisomerase II poisons in mammalian cells. CONCLUSION: Our results point to important differences in the mechanism of cytotoxicity induced by bisdioxopiperazines and topoisomerase II poisons, and suggest that bisdioxopiperazines kill cells by a combination of DNA break-related and DNA break-unrelated mechanisms.
format Text
id pubmed-545072
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-5450722005-01-23 Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells Jensen, Lars H Dejligbjerg, Marielle Hansen, Lasse T Grauslund, Morten Jensen, Peter B Sehested, Maxwell BMC Pharmacol Research Article BACKGROUND: Bisdioxopiperazine anti-cancer agents are inhibitors of eukaryotic DNA topoisomerase II, sequestering this protein as a non-covalent protein clamp on DNA. It has been suggested that such complexes on DNA represents a novel form of DNA damage to cells. In this report, we characterise the cytotoxicity and DNA damage induced by the bisdioxopiperazine ICRF-187 by a combination of genetic and molecular approaches. In addition, the well-established topoisomerase II poison m-AMSA is used for comparison. RESULTS: By utilizing a panel of Saccharomyces cerevisiae single-gene deletion strains, homologous recombination was identified as the most important DNA repair pathway determining the sensitivity towards ICRF-187. However, sensitivity towards m-AMSA depended much more on this pathway. In contrast, disrupting the post replication repair pathway only affected sensitivity towards m-AMSA. Homologous recombination (HR) defective irs1SF chinese hamster ovary (CHO) cells showed increased sensitivity towards ICRF-187, while their sensitivity towards m-AMSA was increased even more. Furthermore, complementation of the XRCC3 deficiency in irs1SF cells fully abrogated hypersensitivity towards both drugs. DNA-PK(cs )deficient V3-3 CHO cells having reduced levels of non-homologous end joining (NHEJ) showed slightly increased sensitivity to both drugs. While exposure of human small cell lung cancer (SCLC) OC-NYH cells to m-AMSA strongly induced γH2AX, exposure to ICRF-187 resulted in much less induction, showing that ICRF-187 generates fewer DNA double strand breaks than m-AMSA. Accordingly, when yeast cells were exposed to equitoxic concentrations of ICRF-187 and m-AMSA, the expression of DNA damage-inducible genes showed higher levels of induction after exposure to m-AMSA as compared to ICRF-187. Most importantly, ICRF-187 stimulated homologous recombination in SPD8 hamster lung fibroblast cells to lower levels than m-AMSA at all cytotoxicity levels tested, showing that the mechanism of action of bisdioxopiperazines differs from that of classical topoisomerase II poisons in mammalian cells. CONCLUSION: Our results point to important differences in the mechanism of cytotoxicity induced by bisdioxopiperazines and topoisomerase II poisons, and suggest that bisdioxopiperazines kill cells by a combination of DNA break-related and DNA break-unrelated mechanisms. BioMed Central 2004-12-02 /pmc/articles/PMC545072/ /pubmed/15575955 http://dx.doi.org/10.1186/1471-2210-4-31 Text en Copyright © 2004 Jensen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jensen, Lars H
Dejligbjerg, Marielle
Hansen, Lasse T
Grauslund, Morten
Jensen, Peter B
Sehested, Maxwell
Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
title Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
title_full Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
title_fullStr Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
title_full_unstemmed Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
title_short Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
title_sort characterisation of cytotoxicity and dna damage induced by the topoisomerase ii-directed bisdioxopiperazine anti-cancer agent icrf-187 (dexrazoxane) in yeast and mammalian cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545072/
https://www.ncbi.nlm.nih.gov/pubmed/15575955
http://dx.doi.org/10.1186/1471-2210-4-31
work_keys_str_mv AT jensenlarsh characterisationofcytotoxicityanddnadamageinducedbythetopoisomeraseiidirectedbisdioxopiperazineanticanceragenticrf187dexrazoxaneinyeastandmammaliancells
AT dejligbjergmarielle characterisationofcytotoxicityanddnadamageinducedbythetopoisomeraseiidirectedbisdioxopiperazineanticanceragenticrf187dexrazoxaneinyeastandmammaliancells
AT hansenlasset characterisationofcytotoxicityanddnadamageinducedbythetopoisomeraseiidirectedbisdioxopiperazineanticanceragenticrf187dexrazoxaneinyeastandmammaliancells
AT grauslundmorten characterisationofcytotoxicityanddnadamageinducedbythetopoisomeraseiidirectedbisdioxopiperazineanticanceragenticrf187dexrazoxaneinyeastandmammaliancells
AT jensenpeterb characterisationofcytotoxicityanddnadamageinducedbythetopoisomeraseiidirectedbisdioxopiperazineanticanceragenticrf187dexrazoxaneinyeastandmammaliancells
AT sehestedmaxwell characterisationofcytotoxicityanddnadamageinducedbythetopoisomeraseiidirectedbisdioxopiperazineanticanceragenticrf187dexrazoxaneinyeastandmammaliancells